Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria

Inclusion Criteria

• - Body weight of 10 kilogram or above
• - Hemolysis with clinical symptom(s) indicative of high disease activity
• - Documented diagnoses of PNH confirmed by high-sensitivity flow cytometry evaluation of red blood cells and white blood cells with granulocyte or monocyte clone size of ≥ 5%
• - Clinically stable after having been treated with eculizumab for at least the past 6 months
• - Participant already assigned to ravulizumab treatment as a specific therapeutic strategy within the current routine clinical practice (this decision has to be made independently and before the enrolment of the participant in the study)
• - Vaccinated against Neisseria meningitidis (according to Summary of Product Characteristics) < 3 years before dosing or at least 2 weeks prior to initiating ravulizumab unless the risk of delaying ravulizumab therapy outweighs the risk of developing a meningococcal infection
• - Signed written informed and privacy consent prior to study participation